Zevra Therapeutics (ZVRA) FCF Margin (2019 - 2026)
Zevra Therapeutics (ZVRA) posted FCF Margin of 16.86% for Q1 2026, up 3.86% on a QoQ basis from 16.23% in Q4 2025, and up 5765.0% year-over-year from 0.29% in Q1 2025.
Zevra Therapeutics (ZVRA) FCF Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics' FCF Margin history runs 8 years deep, the most recent figure standing at 16.86% for Q1 2026.
- Quarterly FCF Margin rose 5765.0% year-over-year to 16.86% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.81% (up 16242.0% YoY) and the FY2025 annual result came in at 2.29%, up 29276.0% from the prior year.
- FCF Margin was 16.86% for Q1 2026 at Zevra Therapeutics, up from 16.23% in the prior quarter.
- Across five years, FCF Margin topped out at 16.86% in Q1 2026 and bottomed at 1167.81% in Q2 2022.
- A 5-year average of 229.32% and a median of 131.78% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin plunged 130618 bps — and 2023, when it surged 106478 bps.
- Zevra Therapeutics' FCF Margin stood at 198.66% in 2022, then surged by 37 bps to 125.62% in 2023, then decreased by 8 bps to 135.28% in 2024, then surged by 112 bps to 16.23% in 2025, then gained by 4 bps to 16.86% in 2026.
- Business Quant data shows ZVRA's FCF Margin at 16.86% in Q1 2026, 16.23% in Q4 2025, and 15.94% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 16.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.86% |
| Dec 31, 2025 | 16.23% |
| Sep 30, 2025 | 15.94% |
| Jun 30, 2025 | -14.74% |
| Mar 31, 2025 | -40.79% |
| Dec 31, 2024 | -135.28% |
| Sep 30, 2024 | -490.96% |
| Jun 30, 2024 | -434.30% |
| Mar 31, 2024 | -471.97% |
| Dec 31, 2023 | -125.62% |
| Sep 30, 2023 | -165.80% |
| Jun 30, 2023 | -103.03% |
| Mar 31, 2023 | -128.27% |
| Dec 31, 2022 | -198.66% |
| Sep 30, 2022 | -240.86% |
| Jun 30, 2022 | -1,167.81% |
| Dec 31, 2021 | -33.50% |
| Sep 30, 2021 | -142.14% |
| Jun 30, 2021 | 138.37% |
| Mar 31, 2021 | -21.37% |